# Takeda

> Takeda is a VC fund in Osaka backing Health Care and Biotechnology. See 61 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Osaka, Japan
- Total investments: 61
- Last investment: Dec 2025
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/719915
- X (Twitter): https://www.twitter.com/takedapharma
- Website: http://www.takeda.com
- Facebook: https://www.facebook.com/takedapharma

Takeda is a VC fund in Osaka focused on Health Care and Biotechnology. Takeda researches, develops, manufactures, sells, markets, imports, and exports pharmaceutical drugs. They offer pharmaceuticals, therapeutics, oncology, and gastroenterology vaccines.

## Contacts

5 contacts available for Takeda. Shizune tracks 10 team members at Takeda. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/takeda-pharmaceutical?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Grant | $5k–$8.7M |
| Corporate Round | $52M–$1.4B |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 27 | 44% |
| Biotechnology | 26 | 43% |
| Pharmaceutical | 14 | 23% |
| Medical | 13 | 21% |
| Therapeutics | 11 | 18% |

50 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 25 | 41% |
| Corporate Round | 7 | 11% |
| Funding Round | 6 | 10% |
| Post-IPO Equity | 6 | 10% |
| Series A | 5 | 8% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 41 | 67% |
| Japan | 7 | 11% |
| China | 2 | 3% |
| Canada | 1 | 2% |
| France | 1 | 2% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew Plump | President, Research & Development | 1 | https://shizune.co/investors/profile/andrew-plump |
| Bin Li | Director of Computational Biology, Takeda Data Science Institute | 0 | https://shizune.co/investors/profile/bin-li |
| Ceri Davies | Head of CNS Drug Discovery Unit | 1 | https://shizune.co/investors/profile/ceri-davies-bcd7 |
| Christopher Barr | Takeda Community Engagement | 0 | https://shizune.co/investors/profile/christopher-barr |
| Masaru Otsuka | Head of Digital Acceleration | 0 | https://shizune.co/investors/profile/masaru-otsuka |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BaseLaunch | The BaseLaunch accelerator supports carefully selected ventures over the course of 15 months and runs in two phases. It provides non-dilutive funding, no strings attached access to its Healthcare Partners, knowledge from highly experienced advisors, as well as a state-of-the-art infrastructure. Furthermore, Baselaunch embeds the ventures deeplywithin the Basel region, one of Europe’s finest biotech ecosystem. Baselaunch is backed by five industry leaders — Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and Roivant Sciences — as well as by other public and private partners. |  | Corporate Round | Dec 16, 2025 |  |
| Beacon Biosignals | Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M | Series B | Nov 13, 2025 |  |
| Innovent Biologics | Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. Theregistered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others. | $100M | Post-IPO Equity | Oct 21, 2025 |  |
| Daily Table | Daily Table is a non-profit grocery food store. |  | Grant | Apr 30, 2025 |  |
| Bulungula Incubator | Bulungula Incubator aims to sustainably end poverty in a generation while enhancing community life and cohesiveness. | $2.2M | Grant | Sep 18, 2024 |  |
| Population Services International | PSI provides life-saving information, products, and services to tackle some of the world’s most pressing health problems so that people can lead healthier, happier, and more productive lives. | $7.1M | Grant | Sep 18, 2024 |  |
| VillageReach | VillageReach is an international NGO headquartered in Seattle, WA with field offices located in Malawi and Mozambique, Africa. Through collaboration with public and private sector partners, VillageReach seeks to increase access to quality healthcare for the world most underserved communities, bringing life-saving innovations to scale andsustainability. VillageReach develops, tests and implements solutions that uniquely address barriers at the lower levels or last mile of healthcare delivery in low-resource communities including medicine availability, human resource constraints, data visibility and lack of infrastructure. | $8.7M | Grant | Sep 18, 2024 |  |
| Reach Out Cameroon | Reach Out Cameroon is a non profit organisation aim is to improve the lives of the most vulnerable people using a community-centred approach. | $8.2M | Grant | Sep 18, 2024 |  |
| Seed Global Health | Seed Global Health strengthens health education and delivery in places facing a dire shortage of health professionals by working with partner countries to meet their long-term health care human resource needs. | $6.3M | Grant | Sep 18, 2024 |  |
| Ascentage Pharma | Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors. | $75M | Post-IPO Equity | Jun 20, 2024 |  |

10 of 61 investments shown.

## Co-investors
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 2 deals together
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 2 deals together
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 2 deals together
- [Innoviva](https://shizune.co/investors/profile/innoviva) — VC Fund, 2 deals together
- [Lightstone Ventures](https://shizune.co/investors/profile/lightstone-ventures) — VC Fund, 2 deals together
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in Japan](https://shizune.co/investors/health-care-investors-japan)
- [Health Care VC Funds in Japan](https://shizune.co/investors/health-care-vc-funds-japan)
- [Medical Investors in Japan](https://shizune.co/investors/medical-investors-japan)
- [Biotechnology Investors in Japan](https://shizune.co/investors/biotechnology-investors-japan)
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)

## FAQ

### What does Takeda invest in?

Takeda invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Grant and Corporate Round stage. Most of the 61 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Takeda's check size?

Takeda typically joins rounds of $5k–$8.7M at Grant and $52M–$1.4B at Corporate Round. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Takeda participates in.

### How do I contact Takeda?

Public channels for Takeda include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Takeda?

The team at Takeda includes Andrew Plump (President, Research & Development), Bin Li (Director of Computational Biology, Takeda Data Science Institute) and Ceri Davies (Head of CNS Drug Discovery Unit), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co